Abstract: It is an object to make it easy to unfold a wheelchair simply by lifting a part of the wheelchair with one hand. A wheelchair includes a folding mechanism that folds a left-side support arm and a right-side support arm. The folding mechanism includes a grip part coupled to the distal end part of the left-side support arm and the distal end part of the right-side support arm. The grip part extends in the pivoting direction of the left-side support arm and the right-side support arm at a time of switching from a folded state to an unfolded state.

Abstract: A telehealth movable vehicle is provided. The telehealth movable vehicle includes a movable part, a fixed member, a slidable member, a bracket, a video/audio transceiver module, and a telescopic rod. The fixed member is affixed to the movable part, and has a guide rail. The slidable member is movably connected to the guide rail. The bracket is affixed to the slidable member. The video/audio transceiver module is disposed on the bracket. The telescopic rod is connected to the fixed member and the slidable member. The telescopic rod is configured to drive the slidable member to move along the guide rail relative to the fixed member.

Abstract: Embodiments herein disclose an extended wheel chair having a wheel chair and an attachment device. The wheel chair comprises a body having each of first body part and a second body part mounted over a frame on the wheel chair. The second body part comprises at least two pins and a flat plate. The wheel chair further comprises an attachment device to be mechanically locked to the body of the wheel chair. The attachment device comprises of a body provided with each of a first slot and a second slot. First pin of the at least two pins is engaged with the first slot and a second pin of the at least two pins is engaged with the second slot.

Abstract: A wheelchair back support adjustment assembly that utilizes a swivel assembly is disclosed. This swivel assembly provides an entirety of an interconnection between the wheelchair back support adjustment assembly and a back support of a wheelchair. The wheelchair back support adjustment assembly may also include a linkage that interfaces with the swivel assembly. Opposite end portions of the linkage are connectable with a corresponding cane of a wheelchair. The configuration of the wheelchair back support adjustment assembly accommodates a variety of adjustments, to correspondingly adjust a back support of a wheelchair when in an installed configuration (e.g., to customize the back support to a user of the wheelchair). These adjustments may be through one or more adjustments of the swivel assembly, one or more adjustments adjustment of the linkage, or both.

Abstract: A patient support apparatus, such as a bed, cot, stretcher, operating table, recliner, or the like, include a litter frame, a support deck, a battery, an AC connector for receiving electrical power, a plurality of motorized actuators, and a control system. The control system limits the amount of electrical power available to the motorized actuators to different levels depending upon whether the AC connector or the battery is powering the patient support apparatus. The control system may also or alternatively change the power available to the motorized actuators depending upon whether a mattress therapy is currently in progress or not. Still further, the control system may pause battery recharging during actuator movement, may utilize one or electronic fuses to control power delivery, and/or wake up sleeping (or shut down) microcontrollers using a specialized network transceiver command that cause the recipient transceiver to wake up its associated microcontroller.

Abstract: A patient transport apparatus with a base, a litter comprising a support surface, and a lift mechanism to facilitate arranging the litter at different heights relative to the base between a plurality of lift configurations including a fully-retracted configuration and a fully-extended configuration. The lift mechanism includes an actuator including a cylinder, fluid reservoir, and a pump driven by a motor to direct hydraulic fluid from the fluid reservoir to the cylinder. A sensor outputs a signal indicative of a magnitude of pressure in the cylinder. A user interface with an input control is provided. A controller determines a target parameter for the motor and, in response to user engagement with the input control, drives the motor at the target parameter to effect movement of the litter relative to the base at a predetermined rate irrespective of a weight of a patient supported on the litter.

Abstract: A massage kit having a foam roller, a massage device, and a removable cover. The massage device includes a flat bottom surface with a curved top surface. Protrusions extend from the massage device and are configured to interact with the removable cover to hold the cover in place on the top surface or the bottom surface of the massage device. The roller includes an opening sized and dimensioned to receive the massage device.

Abstract: A system having an arrangement for supporting an arm of a user is disclosed. The arrangement has an actuator, which is connected to a shoulder element by a joint chain. The joint chain is designed to extend along the shoulder blade of a shoulder of the user and to introduce vertically acting forces into the shoulder element. Moreover, the joint chain is guided by a flexible structure that extends over the shoulder of the user. By virtue of the deformability of the flexible structure, it is possible to ensure that a lifting of the shoulder, resulting from a lifting of a hand of the user, is not impeded.

Abstract: An active orthotic device, e.g. a hand orthosis, is attached to one or more limbs of a human subject and comprises a respective set of actuators (21) for moving a respective limb (1A) among the one or more limbs. A method for controlling the orthotic device comprises obtaining one or more bioelectric signals, [S(t)], from one or more bioelectric sensors (10) attached to or implanted in the human subject; processing the one or more bioelectric signals, [5(t)j, for prediction of an intended application force, FA(t), of the respective limb (1A) onto an object; obtaining a force signal, PA(t), from a force sensing device (22) associated with the respective set of actuators (21) and/or the respective limb (1A); and generating, as a function of a momentary difference, e(t), between the intended application force, FA(t), and the force signal, PA(t), a respective set of control signals, it(t), for the respective set of actuators (21).

Abstract: A conductive structure of a massage roller includes a working circuit board, a conductive base, a conductive plate, two first conductive parts and two second conductive parts. The working circuit board and the conductive plate are positioned at upper and lower ends of the conductive base respectively. The conductive base is provided with at least a pair of accommodating cavities, and conductors are placed in the accommodating cavities. The two first conductive parts are positioned on the bottom surface of the working circuit board, and the first conductive parts are connected with the working circuit board. The two second conductive parts are positioned on the top surface of the conductive plate, and the second conductive parts are connected with the conductive plate; and the top surfaces of the conductors abut against the two first conductive parts, and the bottom surfaces of the conductors abut against the two second conductive parts.

Abstract: The present invention relates to a vibration apparatus, comprising a masturbation cup, comprising a motor, a speed reduction mechanism and rotating body. The output of the motor, after being decelerated by the speed reduction mechanism drive the rotating body to rotate. The rotating body is an eccentric structure, internally provided with a cavity. The motor and the speed reduction mechanism are both arranged in the internal cavity of the rotating body. The present invention also relates to a masturbation cup and vibration rod vibration apparatus, by means of a built-in high-speed rotating ball, centrifugal forces in different directions are generated by means of high-speed rotation of the eccentric ball, such that a cup body of the masturbation cup is driven to move in various directions so that requirements of vibration strength and vibration amplitude can be met, and requirements of high telescopic frequency and strength can also be met.

Abstract: A stimulation device is provided in accordance with one embodiment. The stimulation device includes a chamber which has a flexible wall portion. A drive unit of the stimulation device is in physical communication with the flexible wall portion so as to cause deflections of the flexible wall portion in opposing directions, thereby resulting in a changing volume of the chamber. The changing volume of the chamber results in modulated positive and negative pressures with respect to a reference pressure. An opening of the stimulation device is for applying the modulated positive and negative pressures to a body part. An appendage of the stimulation device may be used as a handle to allow a user to position the stimulation device over the body part. The stimulation device includes a control device for controlling the drive unit.

Abstract: A sexual stimulation device includes a housing, a suction nozzle, a motor, an eccentric rod, and a connecting rod. The motor drives the eccentric rod to rotate. The eccentric rod drives the connecting rod to swing left and right to enable a stimulation member to swing left and right. The stimulation member swings left and right to squeeze the air in a space in the suction nozzle to generate an air vortex. The force generated by the air vortex is to perform 360° massage and stimulation on the female erogenous zone. It effectively enhances the user's experience, and it is easier for the user to have an orgasm.

Abstract: A system and a method for treatment of a disorder in a gastrointestinal tract of a subject, using a treatment protocol, the treatment protocol being based at least in part on data relating to other subjects and their responses to treatment with various treatment protocols.

Abstract: A massage system for a seat of a vehicle includes a drive motor, a sliding member having a hollow pillar shape, a first end of the sliding member being blocked by a plate member and a second end of the sliding member being opened, a housing member having a hollow pillar shape, a first end of the housing member being blocked by a partition and a second end of the housing member being opened, and a drive gear module operably connected to the drive motor, wherein at least one roller member is extended toward the housing member at an edge of the plate member, and at least one cam protruding toward the sliding member is formed at a circumference of the partition, wherein a cam profile is formed at a surface of the cam.

Abstract: A walking aid for taking up a deployment supported force for supporting a person using the walking aid, including a support upper part for engaging around the person, a shaft and a support foot arranged at a lower end of the shaft and having multiple swivelable support legs which can be moved between a storage position in which they are folded out from one another at a predefined angle and the walking aid can be set down on the ground, and a use position in which the support legs are folded together and arranged next to one another and the walking aid can be used, characterized in that the support legs are swivelably retained at a lower end of the shaft, and in that they are designed for taking up the deployment supported force in the use position.

Abstract: A cable tension adjuster for a manually operated, height-adjustable wheeled vehicle. The vehicle includes a brake assembly including a brake cable assembly and a brake cable housing shaped to enclose an excess portion of the brake cable assembly. The brake assembly includes a cable adjuster coupled to the brake cable assembly, where the cable adjuster is enclosed by the brake cable housing. The brake cable housing provides an access port to access the cable tension adjuster.

Abstract: There is disclosed a spa. The spa generally having a unibody shell having a base, a peripheral wall extending from the base up to a rim portion, a basin suspended from the rim portion, and at least one opening in the peripheral wall, the basin, the rim portion, the peripheral wall and the base defining a cavity therebetween, the at least one opening exposing the cavity, the base having a pair of channels recessed from the base towards the cavity; and a modular panel having a main panel covering the opening while exposing the pair of channels, and a subpanel engageable to the main panel and covering at least partially the pair of channels.

Abstract: A therapeutic nanoparticle diffusion system includes at least one rubber bootie; a foot bath; and a nanoparticle composition. The rubber bootie is adapted to accommodate a user's foot and the nanoparticle composition. The foot bath has a predetermined height, a vibrational base, and a heating element attached. A therapeutic method of administering nanoparticles includes providing the bootie and the foot bath; adding water to the foot bath; donning the bootie; resting the foot and the bootie in the foot bath; adding a nanoparticle composition to the bootie; activating the heating element and the vibration element; resting the subject's foot in the nanoparticle composition; doffing and emptying the bootie into the foot bath; and soaking the subject's foot in the foot bath. The temperatures and times are predetermined.

Abstract: Caps for sealing assemblies for sealing glass containers and maintaining container closure integrity at ?80° C. or less are disclosed. The caps include a cap skirt having an annular body and a crimp region. The crimp region is a crimpable metal. The annular body of the cap skirt has a coefficient of thermal expansion (CTE) greater than a CTE of a metal consisting of aluminum, a stiffness greater than or equal to 2 times a stiffness of the crimp region, or both. The greater CTE, stiffness, or both of the cap skirt increase the seal pressure and contact area between the stopper and glass container when cooled to ?80° C. or less. The caps enable the sealing assemblies to maintain a helium leakage rate of the sealed glass container of less than or equal to 1.4×10?6 cm3/s at ?80° C. or less.

Abstract: A method of packaging a two component composition into a dual vial (100), wherein the dual vial (100) comprises a single continuous piece of material arranged to provide both a first vial (110) and a second vial (120), the method comprising providing a second component of the composition into a volume, of the second vial (120), surrounding the first vial (110), providing a first component of the composition into a first vial (110), wherein the first vial (110) is nested within a second vial (120), and closing the first vial (110) and the second vial (120).

Abstract: A drug container assembly for use with a parenteral drug delivery device is disclosed. The container assembly includes a container configured to hold the medication and an intermediate port connector. The port connector may be fixedly coupled to the container and removably coupled to the delivery device in a convenient, reliable, and sealed manner. In use, the port connector may convey the medication from the container to the delivery device for delivery to the patient.

Abstract: In an embodiment, a user operated pneumatic sterile liquid compounding device enables a user to easily and rapidly perform a sterile liquid compounding operation. The frame of the device is configured to receive a syringe with a needle inserted into a sterile vial. A pneumatic cylinder including a pusher rod connected to a pusher plate engages the top of the syringe plunger. Initially a user-operated lever is in an “UP” position. When the lever is moved to a “DOWN” position, the device engages the pusher plate to move the plunger down to inject the liquid in the syringe into the sterile container. The compounding device is powered by pressured gas from a cartridge via an adjustable pressure regulator, a pressure release valve, and a pneumatic cylinder valve connected to the pneumatic cylinder to allow pressured gas applied to the pneumatic cylinder to raise and lower the rod.

Abstract: Methods and compositions for increasing LDL receptor levels in a plurality of cells are disclosed. For example, the methods include providing to the cells a curcumin composition that is at least 15% curcumin II or at least 5% curcumin III, in order to increase LDL receptor levels. In addition, compositions for increasing LDL receptor levels in a plurality of cells are disclosed, which include a curcumin composition consisting of at least 15% curcumin II or at least 5% curcumin III (or combinations of such curcuminoids), along with a pharmaceutically-acceptable solvent, filler, or carrier. Still further, methods and compositions for decreasing MSK1 levels in a plurality of cells are disclosed, which involve administering a curcumin III-enriched composition to the cells.

Abstract: The disclosure provides a dosing regimen utilizing an oral extended release formulation for the treatment of treatment-resistant depression and treatment-resistant anxiety.

Abstract: The present invention relates to a pharmaceutical combination for use in the treatment, prevention and/or stabilization of age-related diseases and/or degenerative diseases. In particular, said pharmaceutical combination comprises a biguanide and an acetylcholinesterase inhibitor and/or an N-oxide, a hydrate, a pharmaceutically acceptable salt or solvate thereof. The invention is further also directed to the use of said pharmaceutical combination for prevention, stabilization and/or reduction of age-related complaints and/or degenerative complaints; and for improving a measure of life span and/or health span.

Abstract: The invention relates to a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, for use in treating type 2 diabetes. The invention also relates to the use of a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating type 2 diabetes. The invention also relates to a method of treating type 2 diabetes using a DPP-IV inhibitor (preferably vildagliptin or a pharmaceutically acceptable salt thereof), and metformin or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein according to some embodiments is a method for decreasing the potential for adverse events from solriamfetol in an infant fed breast milk obtained from a subject treated with solriamfetol comprising: orally administering the solriamfetol to the subject at a daily dose of about 37.5 mg to about 300 mg; and feeding the infant breast milk from the subject at least about 5 hours after administering the solriamfetol to the subject, thereby decreasing potential for adverse events from solriamfetol in an infant.

Abstract: Methods of treating a valvular heart disease are provided. Methods for treating valvular heard disease include administering to a subject a therapeutically effective amount of at least one hedgehog pathway inhibitor. Also provided are methods for reducing fibrosis in a subject, which comprise administering to the subject a therapeutically effective amount of at least one hedgehog pathway inhibitor.

Abstract: The present disclosure relates to dispersible pharmaceutical compositions comprising N—((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier.

Abstract: Ketogenic compositions include a non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the R-enantiomer. The compositions are enriched with the R-enantiomer to elevate ketone bodies and increase the rate at which ketosis is achieved yet contains an amount of the S-enantiomer to provide alternative benefits. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for increasing ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and a non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate, wherein the non-racemic mixture of R-beta-hydroxybutyrate and S-beta-hydroxybutyrate contains from about 50.5% to 99.

Abstract: The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.

Abstract: A compound having the formula (I) R1-COOH. R1 is an alkyl or alkenyl group having a C7-11 backbone, optionally branched with a C1-6 alkyl group at any C position in the backbone, or a pharmaceutically acceptable salt, amide or ester thereof. The backbone of the alkyl or alkenyl group, and/or the branched alkyl groups, are optionally interrupted by one or more heteroatoms, provided that when R1 is an alkyl group having a C7 backbone, the branching does not consist only of a hexyl group at the a carbon of R1, or only of a methyl group at the ? carbon of R1, or of only single methyl groups at both the ? and ?-1 carbons of R1, and provided that when R1 is an alkyl group having a C8 or C11 backbone, the branching does not consist only of a propyl group at the a carbon of R1.

Abstract: The invention relates to a new use of Tris (dibenzylideneacetone) dipalladium (Tris DBA). The invention provides a pharmaceutical composition comprising Tris DBA, and a use of the pharmaceutical composition for treating autoimmune diseases, such as, Multiple sclerosis, psoriasis, asthma, systemic lupus erythematosus and lupus nephritis.

Abstract: Problem: To provide a topical composition having excellent permeability in the stratum corneum. Solution: A topical composition is prepared that comprises: (A) one antifungal agent or two or more antifungal agents selected from the group consisting of tolnaftate and pharmaceutically acceptable salts thereof; and (B) at least one compound selected from the group consisting of ester compounds of fatty acids having from 8 to 18 carbon atoms and dihydric alcohols having from 2 to 4 carbon atoms, lysine acyl glutamate, lysine diacyl glutamate, pharmaceutically acceptable salts of lysine acyl glutamate or lysine diacyl glutamate, diethylene glycol-based glycol ethers, cyclohexanedicarboxylic acid polyoxyethylene alkyl ethers, mannosylerythritol lipids, and sucrose fatty acid esters.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

Abstract: This document relates to non-covalently bound complexes including Docetaxel and human serum albumin, and to compositions comprising such complexes. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the composition is a clear aqueous solution when the composition is dissolved in an aqueous solution, and wherein the composition has a solubility in an aqueous solution of at least 10 mg/ml. This document also relates to compositions comprising Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. This document also relates to compositions consisting essentially of Docetaxel and human serum albumin, wherein the Docetaxel and the human serum albumin in the composition have a weight ratio from about 1:50 to about 1:1000. The pH of the docetaxel compositions of the present disclosure is from about 5 to about 8.

Abstract: Minimally invasive treatment methods for benign prostatic hyperplasia (BPH) tissue. A system includes a sustained release formulation comprising a cytostatic or cytotoxic drug, and an applicator or delivery system for local delivery of a composition comprising or consisting essentially of the sustained release formulation to the prostate. The applicator containing the composition is characterized by a KIR value of between 40 and 400 Centipoise per unit area.

Abstract: The invention relates to a solid ?9-THC composition containing ?9-THC and a powder former and having a molar ratio of ?9-THC to powder former to form a flowable ?9-THC powder. The powder former is selected from the group consisting of adenine, aspartame, caffeine, lactose, mannitol, nicotinamide, ?-nicotinamide adenine dinucleotide, pipecolic acid, saccharin, aspartic acid, glutamic acid, glutamine, histidine, leucine, methionine, phenylalanine, proline, serine, tryptophan, valine, Epigallocatechin Gallate (EGCG), 2-Hydroxypropyl-beta-cyclodextrin (HPbCD), and Trimethyl-beta-cyclodextrin (TOMBC) and mixtures thereof. The invention also relates to methods of making a solid ?9-THC composition of the invention. The ?9-THC may be synthetic ?9-THC or may be extracted ?9-THC.

Abstract: A pharmaceutical composition is prepared from the following raw materials (in parts by weight): silybin (8.75-60), phospholipid (15-65), a Pu'er tea extract (25-200), and vitamin E (6.25-40). The composition has the effect of treating non-alcoholic fatty liver diseases.

Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.

Abstract: Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.

Abstract: Disclosed herein are methods for use of clemizole for the treatment of a subject in need thereof. Uses include methods of treating inflammatory conditions. Uses also include methods of treating non-alcoholic steatohepatitis in a subject.

Abstract: Certain embodiments are directed to methods and compositions for treating cancer, specifically colorectal cancer by administering an aldose reductase inhibitor and an immune checkpoint inhibitor to a subject in need thereof. Certain embodiments are directed to methods of treating a subject having cancer comprising, administering (i) a composition comprising an aldose reductase specific inhibitor and (ii) a composition comprising an immune checkpoint inhibitor to the subject having melanoma, head and neck, or colorectal cancer.

Abstract: A 4-chloro-N?-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The present disclosure provides a photocurable hydrogel loaded with VH298-modified exosome and a method of preparation and use thereof, belonging to the technical field of medical materials. In the present disclosure, an engineered exosome (VH-EVs) is prepared by combining an exosome with VH298, a hypoxia-inducible factor 1 alpha (HIF-1?) stabilizer; and a solid auxiliary material is loaded by a GelMA hydrogel. The material is not only conducive to sustained release of the engineered exosome, but improves angiogenesis and accelerate wound healing, showing a relatively high value for use.

Abstract: The present invention provides compositions and methods for treating diseases or disorders using a therapeutically effective amount of a rapid-acting antidepressant (RAAD) and a therapeutically effective amount of a mTOR inhibitor and/or immunosuppressant. In certain embodiments, the RAAD and the mTOR inhibitor and/or immunosuppressant are part of a single pharmaceutical composition.

Abstract: The present application relates generally to compounds useful for the treatment and/or enhancement of cognitive dysfunction and negative symptoms associated with CNS disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.

Abstract: Provided herein are methods of treating, preventing, managing, and/or ameliorating hypotension related to administration of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cancer patient, wherein the methods comprise administering a combination comprising 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or a mixture of stereoisomers, pharmaceutically acceptable salt, tautomer, prodrug, solvate, hydrate, co-crystal, clathrate, or polymorph thereof and a glucocorticoid receptor agonist, an interleukin-1 receptor antagonist, or an interleukin-1? blocker.

Abstract: The present disclosure provides methods for the treatment of migraine by the administration of atogepant or a pharmaceutically acceptable salt thereof.